Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
Professional programme which provides all professional services staff with development opportunities and the encouragement to reach their full potential. With almost 5,000 professional services jobs in a wide
-
£46,735 to £55,755 with potential progression once in post to £62,728 Grade: 8 Full Time, Permanent Closing date: 31st August 2025 Interview date: W/c 15th September 2025 Academic Development Programme
-
the city and beyond, support them to succeed, and celebrate their success. We are committed to helping the people who work here to develop through our sector-leading Birmingham Professional programme which
-
July 2025 Background To create and contribute to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Role
-
, endocrine aspects of fertility and miscarriage; metabolic health in pregnancy). In addition, there is ready access to collaboration with mathematical modellers and computer scientists through the research
-
at the University of Birmingham is pleased to offer a Part-Time Research Fellow post funded through the NIHR DEMCOMM Fellowship Programme. This post supports a motivated qualitative researcher to contribute
-
activities within an established research programme and/or specific research project. This project involves addressing the issue of triboelectric energy nanogenerators to power ingestible devices. Ingestible
-
. Contribute to the planning and organising of the research programme and/or specific research project. Co-ordinate own work with others to avoid conflict or duplication of effort. Knowledge of the protected
-
sector-leading Birmingham Professional programme which provides all professional services staff with development opportunities and the encouragement to reach their full potential. With almost 5,000
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor